GSK plc (GSK)
| Market Cap | 103.92B +33.9% |
| Revenue (ttm) | 43.29B +4.0% |
| Net Income | 7.70B +84.9% |
| EPS | 3.75 +86.6% |
| Shares Out | 4.02B |
| PE Ratio | 13.50 |
| Forward PE | 10.50 |
| Dividend | $1.77 (3.40%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 5,503,301 |
| Open | 52.04 |
| Previous Close | 51.35 |
| Day's Range | 51.73 - 52.67 |
| 52-Week Range | 36.75 - 61.70 |
| Beta | 0.30 |
| Analysts | Hold |
| Price Target | 58.08 (+11.74%) |
| Earnings Date | Jul 28, 2026 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for GSK stock is "Hold." The 12-month stock price target is $58.08, which is an increase of 11.74% from the latest price.
News
GSK sees 70p per share dividend for FY26
07:36 EDT GSK (GSK) sees 70p per share dividend for FY26
GSK initiates ‘Accelerate Growth’ program
The company said, “Following review, the company has identified asset accelerations – across 18 indications – for 7 late-stage products in Oncology, Respiratory, Hepatology and Vaccines. GSK (GSK) now...
GSK reports Q2 core EPS 50.5p, up 9% at CER
Reports Q2 revenue GBP 8.4B, +5% AER; +5% CER. “GSK (GSK) has delivered another quarter of strong core results performance, with our key growth drivers performing well.We remain focused on…
GSK beats second-quarter profit estimates, launches $2.52 billion cost savings drive
GSK on Tuesday beat second-quarter profit expectations and launched a £1.9 billion ($2.52 billion) cost savings drive as the British drugmaker seeks to ramp up its development pipeline to sup...
GSK to invest £400 million in Britain over 3 years as it ramps up R&D efforts
British drugmaker GSK said on Tuesday that it will invest £400 million ($531.12 million) over 3 years in the country, including a new R&D center in Cambridge as part of its plans to develop medicine...
GSK, Hansoh's cancer drug meets main goal of bone cancer trial
GSK on Tuesday said partner Hansoh Pharmaceutical's experimental drug Ris-Rez met its main goal of keeping an aggressive bone cancer from worsening in a late-stage trial, just weeks after ...
AI sell-off deepens as chip stocks slump in market retreat - business live
Rolling coverage of the latest economic and financial news The rout in AI stocks also followed a report by the Information that China has begun mass production of homegrown deep ultraviolet, or DUV, c...
GSK Looks 17.5% Overvalued on GF Value⢠as Dividend Sustainability Comes into Focus
GSK Looks 17.5% Overvalued on GF Value⢠as Dividend Sustainability Comes into Focus
GSK Looks 17.4% Overvalued on GF Value⢠as Dividend Sustainability Remains a Key Focus
GSK Looks 17.4% Overvalued on GF Value⢠as Dividend Sustainability Remains a Key Focus
GSK Looks 18.3% Overvalued on GF Value⢠as Q2 Earnings Forecasts a Sharp EPS Drop
GSK Looks 18.3% Overvalued on GF Value⢠as Q2 Earnings Forecasts a Sharp EPS Drop
Earnings To Watch: GSK PLC (LSE:GSK) Reports Q2 2026 Result
Earnings To Watch: GSK PLC (LSE:GSK) Reports Q2 2026 Result
Weekly Buzz: AZN, GSK JNJ Approvals; CUV Layoff, REGN, HALO, Samsun Deals, LLY, CLDX Data
(RTTNews) - This week, the biotech sector was marked by FDA and EU approvals, strategic acquisitions, and a major workforce restructuring. Clinical trial updates delivered both breakthroughs and setba...
GSK Reinstated by Citigroup -- Rating Set to Neutral
GSK Reinstated by Citigroup -- Rating Set to Neutral
GSK Receives Approval for Shingrix Prefilled Syringe
GSK Receives Approval for Shingrix Prefilled Syringe
GSK Canada announces approval of Shingrix in prefilled syringe
GSK (GSK) Canada announced the approval of Shingrix in a prefilled syringe. This new presentation removes the need to reconstitute separate vials prior to administration.
GSK Receives Neutral Rating from Citi with 2,100 GBp Price Target
GSK Receives Neutral Rating from Citi with 2,100 GBp Price Target
GSK resumed with a Neutral at Citi
Citi resumed coverage of GSK (GSK) with a Neutral rating and 2,100 GBp price target following the Nuvalent acquisition. The firm views the deal as “sensible” but says GSK has…
FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca
The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants diges...
AstraZeneca 'magic' faces rare test after trial failure, share slide
AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and mai...
GSK Wins Early FDA Approval For Jideytro In ROS1-Positive Lung Cancer For Adults
(RTTNews) - GSK plc (GSK) announced that the US Food and Drug Administration (FDA) has approved Jideytro, chemically known as zidesamtinib, for the treatment of adult patients with locally advanced or...
GSK Enters Lung Cancer Therapy Market with FDA Approval of Jideytro
GSK Enters Lung Cancer Therapy Market with FDA Approval of Jideytro
GSK Receives FDA Approval for Jideytro to Treat ROS1-Positive Lung Cancer
GSK Receives FDA Approval for Jideytro to Treat ROS1-Positive Lung Cancer
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease1 Next-generation design aims to address key efficacy a...
GSK reports Jideytro approved by FDA for ROS1-positive NSCLC
GSK (GSK) announced the U.S. Food and Drug Administration has approved Jideytro, a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-s...
US FDA approves GSK's lung cancer drug
GSK said on Wednesday the U.S. FDA has approved its drug for adults with a form of lung cancer who have previously received a targeted therapy.